



INTERNATIONAL COMMISSION ON THE
CLINICAL USE OF HUMAN GERMLINE GENOME EDITING

First Meeting

August 13, 2019

**National Academy of Sciences Building
Lecture Room and Room 125 (Overflow)
2101 Constitution Avenue, NW
Washington, DC 20418**

AGENDA

Meeting Objectives:

To understand study goals

To obtain information to assist in addressing study's Statement of Task

These sessions are open and on the record; they will be webcast. All times are EDT.

8:30 AM **Welcome and Introductions** - *Commission Co-chairs*

Kay E. Davies, Ph.D., Dr Lee's Professor of Anatomy, University of Oxford
Richard P. Lifton, M.D., Ph.D., President, The Rockefeller University

8:40 AM **Discussion of the Commission's Statement of Task**

Welcome and Presentation of the Task from the Co-Chairs of the International Oversight Board

Victor Dzau, M.D., President, National Academy of Medicine
John Skehel, Ph.D., Vice-President and Biological Secretary, UK Royal Society

Perspectives from Organizations Providing Financial Support for the Commission

Carrie Wolinetz, Ph.D., Chief of Staff and Associate Director for Science Policy, US National Institutes of Health

9:20 AM **Presentation by World Health Organization (WHO) Expert Advisory Committee on Developing Global Standards for Governance and Oversight of Human Genome Editing**

Margaret Hamburg, M.D., Co-chair of WHO Expert Advisory Committee and National Academy of Medicine Foreign Secretary

9:50 AM *Break*

- 10:10 AM **Discussion of the State of Understanding of Genetics and Genetic Manipulation**
Session Moderator: Eric Lander, Ph.D., President and Founding Director
 Broad Institute of MIT and Harvard
- Aravinda Chakravarti, Ph.D.,** Director, Center for Human Genetics and Genomics, New York University School of Medicine
Sarah Teichmann, Ph.D., Head of Cellular Genetics and Senior Group Leader, Wellcome Sanger Institute – *via videoconference*
Chad Cowan, Ph.D., Assistant Professor of Medicine, Harvard Stem Cell Institute
Britt Adamson, Ph.D., Assistant Professor of Molecular Biology, Princeton University
- 12:00 PM *Lunch (box lunches will be available for attendees)*
- 1:00 PM **Translational Pathways from Laboratory to Therapy: Somatic Genome Editing, Perspectives from the Field**
Session Moderator: Anna Wedell, M.D., Ph.D., Professor and Head of the Centre for Inherited Metabolic Diseases, Karolinska Institute
- Matthew Porteus, M.D., Ph.D.** Professor of Pediatrics, Stanford University
Sandy Macrae, Ph.D. President and Chief Executive Officer, Sangamo Therapeutics
Bruce Levine, Ph.D., Barbara and Edward Netter Professor in Cancer Gene Therapy, University of Pennsylvania
Vic Myer, Ph.D., Chief Technology Officer, Editas Medicine
- 2:45 PM *Break*
- 3:10 PM **Translational Pathways from Laboratory to Therapy: Somatic Genome Editing, Perspectives from Regulatory Bodies**
Session Moderator: Robert Califf, M.D., Professor of Cardiology and Professor of Medicine, Duke University and Advisory, Verily Life Sciences
- Denise Gavin, Ph.D.** Office of Tissues and Advanced Therapies, US Food and Drug Administration
- 4:00 PM **Translational Pathways from Laboratory to Therapy: Somatic Genome Editing, Perspectives from Potential Patient Communities**
Session Moderator: Susan Golombok, Ph.D., Professor and Director of the Centre for Family Research, University of Cambridge
- Sharon Terry,** President and CEO, Genetic Alliance
Sarah Norcross, Director, Progress Educational Trust – *via videoconference*
- 5:00 PM **Public Comment Period**
- 5:30 PM **Adjourn Open Session**